Women have much higher prevalence of severe obesity than men [2], and are typically more likely to engage with health (and preventive) services [43], engage with weight management services, and discuss weight loss with healthcare professionals [24], which may facilitate greater access to emerging treatments like GLP-1 and GLP-1/GIP medications. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.